Introduction {#s1}
============

Adult skeletal muscle exhibits a dramatic capacity to regenerate after injury owing to the presence of satellite cells (SCs), the resident muscle stem cells. SCs reside underneath the basal lamina in a quiescent state, and upon injury, become activated to generate a pool of myogenic progenitors (MPs) that differentiate and fuse to each other or existing myofibers to restore structure and function to muscle ([@bib34]; [@bib47]). While SCs are clearly necessary for efficient regeneration after acute injury ([@bib17]; [@bib25]; [@bib36]), the role of SCs during adult muscle hypertrophy and maintenance is much less understood. Moreover, the regulation of myogenic fusion is relatively unknown compared to the knowledge associated with activation, proliferation, and differentiation of SCs. Elucidation of the magnitude of fusion, and the associated molecular regulation of the fusion process, for adult muscle hypertrophy may lead to strategies that augment loss of muscle mass due to chronic disease and aging.

Load-induced hypertrophy is a desired adaptation of exercise resulting in an increase in skeletal muscle mass, thereby enhancing overall size and function of the affected muscles. Fundamentally, skeletal muscle hypertrophy occurs when the rates of muscle protein synthesis exceed those of protein degradation. In addition to activation of protein synthesis pathways directly in the myofiber, a myofiber could hypertrophy through fusion of SCs leading to a greater capacity for transcription of contractile machinery. The contribution of SCs for hypertrophy was initially justified through the concept of the myonuclear domain ([@bib6]), which postulates a coordinated increase between myonuclei number and cytoplasm volume in order to maintain a constant domain size ([@bib41]; [@bib42]). Moreover, myonuclear accretion precedes an increase in skeletal muscle size ([@bib5]), and loss of serum response factor (Srf) in the myofiber blunts hypertrophy potentially through a SC-mediated mechanism ([@bib15]), altogether implicating a role for fusion during hypertrophy. Studies utilizing diphtheria toxin (DTA)-mediated ablation of SCs have revealed that effective myofiber hypertrophy occurs in the absence of satellite cells and that SCs are not required to maintain muscle mass during aging ([@bib13]; [@bib27]), however SC ablation leads to impaired coordination and diminished muscle performance ([@bib18]). Additionally, SCs contribute to myofibers during aging of sedentary mice although SC activity was not globally required to maintain muscle size ([@bib21]; [@bib33]). Recently, a report utilizing a similar DTA SC ablation model indicates that effective myofiber hypertrophy does not occur in the absence of SCs ([@bib10]). Thus, there is no consensus regarding the contributions of SCs during adult skeletal muscle hypertrophy, highlighting the need for more independent models that assess the biology of SC activity.

Myomaker (*Tmem8c*) is a muscle-specific membrane protein necessary for fusion of embryonic and adult MPs ([@bib29]). In adult muscle, myomaker expression is undetectable but rapidly induced in SC descendants after cardiotoxin (CTX) injury. In this acute injury setting where there is complete destruction of the muscle architecture, the ensuing restoration is the sole responsibility of SCs. Here, all MPs exhibit upregulation of myomaker, and we have shown that fusion is more efficient if both fusing cells express myomaker ([@bib28]). The regulation and function of myomaker in the SC or myofiber compartment in an environment where myofibers are maintained and not destroyed, such as through increased workload and exercise, is unknown.

To investigate the role of myomaker-mediated fusion in skeletal muscle hypertrophy, we explored the expression of myomaker on SCs and myofibers, and generated fusion-incompetent SCs through targeted deletion of myomaker. We show that myomaker is upregulated in SCs upon muscle overload (MOV), but significant activation of myomaker within the myofiber is not detected. In the absence of myomaker induction in SCs, we report an impaired hypertrophic response to MOV, which is associated with a failure to activate Akt/mTOR-mediated protein synthesis within the myofiber. Collectively, our findings demonstrate that effective SC fusion is required for optimal muscle hypertrophy following a load-induced stimulus.

Results {#s2}
=======

Dynamic expression of myomaker during muscle overload coincides with fusion {#s2-1}
---------------------------------------------------------------------------

To determine the regulation of MP fusion during adult skeletal muscle hypertrophy, we first assessed the temporal kinetics of myomaker expression after MOV. In wild-type (WT) mice at baseline, myomaker mRNA and protein are not readily detected in muscle, however myomaker is acutely induced after MOV ([Figure 1A and B](#fig1){ref-type="fig"}). Expression of myomaker peaked 7 days after MOV, and was down-regulated at later time points. To elucidate if myomaker was induced in activated MPs or by the myofiber during MOV, we analyzed *Tmem8c*^LacZ/+^ mice, which contain a *LacZ* cassette in intron 1 of the myomaker locus ([@bib30]). This allele results in exon 1 of myomaker splicing with *LacZ*, generating a transcript with exon 1 of myomaker, and an internal ribosome entry site (IRES) that allows independent translation of *LacZ*. Thus, in this system *LacZ* serves as a readout for myomaker transcription but not myomaker localization. X-gal staining of the plantaris muscle from *Tmem8c*^LacZ/+^ mice at multiple time points after MOV revealed detectable *LacZ* in discrete locations surrounding the myofiber at day 3 of MOV, and in myofibers at later stages of MOV ([Figure 1C](#fig1){ref-type="fig"}). To understand the myogenic state of the different types of LacZ^+^ cells we stained serial sections with either x-gal or embryonic myosin (myh3), a marker of muscle differentiation. Here we observed a population of large LacZ^+^ cells and a population of small LacZ^+^ cells that were in the presumptive SC position ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). We classified the large LacZ^+^ cells as myofibers due to their size, and these were either myh3^+^ or myh3^-^. For myofibers, LacZ^+^ myh3^+^ cells exhibited stronger x-gal staining compared to the LacZ^+^ myh3^-^ cells (punctate staining) suggesting that the former population are de novo fibers formed from the fusion of MPs ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). We interpret the punctate LacZ^+^ myh3^-^ myofibers as existing fibers that have fused with a MP. The population of small LacZ^+^ cells were either myh3^+^ (differentiated myocytes) or myh3^-^ (MPs), and we classified these as the non-myofiber population ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). Quantification of these populations multiple days after MOV revealed an increase in myomaker-expressing MPs at the early stages of MOV (days 3 and 7), followed by a reduction at later stages of MOV (days 10 and 14) ([Figure 1C](#fig1){ref-type="fig"}). In contrast, the majority of LacZ^+^ myofibers were observed at later stages of MOV, with negligible occurrence at 3 days after MOV. Thus, myomaker exhibits a contrasting expression pattern in MPs compared to the myofiber compartment in response to a load-induced stimulus.10.7554/eLife.20007.003Figure 1.Regulation of myomaker activation and fusion during load-induced hypertrophy.Myomaker expression at various time points after MOV was assessed by qPCR (**A**), and western blot analysis (**B**), showing induction of myomaker at all stages of MOV (n = 2--4 mice). (**C**) *Tmem8c^LacZ/+^* mice were subjected to MOV and plantaris sections were X-gal stained at multiple time points after surgery. LacZ, a surrogate for myomaker expression, was observed in MPs (arrows) during the early stages of MOV, and in myofibers (arrowheads) in the later stages of MOV. Quantification of the number of LacZ^+^ non-myofibers indicates myomaker is robustly activated in MPs at day 3 and day 7 of MOV but the number is reduced at day 10 and day 14 (n = 3--5 mice). Quantification of LacZ^+^ myofibers demonstrates the majority of expression occurs at day 7 and day 10 after MOV (n = 2500--4,100 myofibers from 3--5 independent mice). (**D**) Fusion of MPs with myofibers was assessed by labeling proliferating cells with BrdU and tracking their incorporation into a myofiber, identified by immunostaining with a dystrophin antibody. Mice were subjected to MOV and treated with BrdU during the initial 7 days or the last 7 days after MOV. Fusion was scored as a BrdU^+^ nucleus within a dystrophin^+^ myofiber as depicted by the arrows. Quantification of the percentage of myofibers containing a BrdU^+^ nucleus shows an increased labeling of fusion competent satellite cells during the first 7 days of MOV, which correlates with the highest expression of myomaker in satellite cells (n = 380--1,511 myofibers from 3--9 independent mice). Data are represented as mean ± SEM, **\***p\<0.05. Scale bars: 50 μm, except inset in (**D**) which represents 25 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.20007.003](10.7554/eLife.20007.003)10.7554/eLife.20007.004Figure 1---figure supplement 1.Day 7 MOV serial sections were stained with x-gal or immunostained with laminin and embryonic myosin (myh3) antibodies.Two populations of LacZ+ myofibers were observed. One exhibited punctate x-gal and was myh3- (stars) thus representing existing fibers that have fused with a MP. The second myofiber population exhibited stronger x-gal staining and was myh3+ (blue arrows) and these represent de novo myofibers. We also observed two different populations of small cells exhibiting x-gal staining, which we classify as non-myofiber. The first population was LacZ+ myh3+ (green arrows) which indicate differentiated myocytes, whereas LacZ+ myh3- (magenta arrows) depict myogenic progenitors.**DOI:** [http://dx.doi.org/10.7554/eLife.20007.004](10.7554/eLife.20007.004)

To determine if the kinetics of myomaker expression temporally coincides with fusion of MPs during MOV, we examined fusion through 5-bromo-2\'-deoxyuridine (BrdU) labeling of proliferating cells. After synergist ablation surgery, WT mice were treated with BrdU either during the initial or final seven days of the overload stimulus, and fusion was defined as the incorporation of a BrdU^+^ nucleus within a dystrophin^+^ myofiber. Labeling of fusion-competent MPs during the first 7 days of MOV resulted in a greater percentage of myofibers containing a BrdU^+^ nucleus compared to labeling during the final 7 days of MOV ([Figure 1D](#fig1){ref-type="fig"}). While these data indicate that fusion-competent MPs are generated throughout the MOV stimulus, there is greater labeling of fusogenic cells during the initial stages of MOV when myomaker-LacZ^+^ MPs are more prominent, suggesting a temporal relationship between myomaker expression and fusion.

Myomaker is activated primarily in muscle progenitors {#s2-2}
-----------------------------------------------------

While MP expression of myomaker-LacZ indicates that myomaker is actively transcribed in progenitor cells, LacZ activity in myofibers could result from fusion with a LacZ^+^ MP or direct transcription of myomaker-LacZ from a myonucleus. To determine the source of LacZ in myofibers during MOV, we blocked the ability of MPs to fuse through genetic deletion of myomaker. *Tmem8c*^LacZ/loxP^ mice were bred with satellite cell-specific Cre recombinase (*Pax7*^CreERT2/+^) mice ([@bib24]), and subsequently treated with tamoxifen to genetically delete myomaker in muscle progenitor cells (myomaker scKO). Controls include tamoxifen-treated *Tmem8c*^+/+^; *Pax7*^CreERT2/+^ mice, or vehicle-treated *Tmem8c*^LacZ/loxP^; *Pax7*^CreERT2/+^ mice ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Mice were injected with tamoxifen for 5 consecutive days prior to MOV and maintained on a tamoxifen dosage throughout the protocol. qPCR analysis confirmed the efficiency of this tamoxifen-based strategy, as myomaker expression was eliminated in myomaker scKO muscle compared to control muscle 7 days after MOV ([Figure 2A](#fig2){ref-type="fig"}). To be certain that this model maintains the presence of SCs during MOV we crossed the *Rosa26*^mTmG^ genetic lineage reporter with our *Tmem8c*^LacZ/loxP^; *Pax7*^CreERT2/+^ mice ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). This results in a ubiquitously expressed membrane-targeted tdTomato (mTom), but upon Cre-mediated recombination tdTomato is excised allowing membrane-GFP expression. These mice were subjected to MOV and assayed for the presence of mGFP^+^ cells (MPs) using flow cytometry. We observed a non-significant reduction in mGFP^+^ cells after MOV in myomaker scKO muscle ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). We also performed immunostaining for Pax7, which revealed no major differences in SC number during MOV when normalized to fiber number ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). These results indicate that while there could be subtle alterations in SC dynamics, the myomaker scKO model does not significantly alter the frequency of muscle stem cells.10.7554/eLife.20007.005Figure 2.Myomaker is mainly expressed in MPs and not myofibers during MOV.(**A**) *Tmem8c^LacZ/loxP^; Pax7*^CreERT2/+^ mice (myomaker scKO) were treated with tamoxifen to ablate myomaker specifically in SCs. Control mice include vehicle-treated *Tmem8c^LacZ/loxP^; Pax7*^CreERT2/+^ mice and tamoxifen-treated *Tmem8c^+/+^; Pax7*^CreERT2/+^ mice. Mice were subjected to MOV and myomaker expression was assessed through qPCR analysis 7 days post-surgery showing that myomaker was efficiently deleted in myomaker scKO muscle (n = 3--4 independent mice). (**B**) To determine the origin of LacZ staining observed in control myofibers ([Figure 1C](#fig1){ref-type="fig"}), MOV was performed on myomaker scKO mice and sections were X-gal stained. Ablation of myomaker in SCs results in restriction of myomaker expression to MPs and lack of expression in the myofiber. Quantification of LacZ^+^ non-myofibers shows a significant increase at day 7 in myomaker scKO mice compared to control mice because myomaker scKO are fusion defective and thus remain outside the myofiber (n = 3--5 mice). The percentage of LacZ^+^ myofibers are reduced in *myomaker*^scKO^ mice suggesting that myofiber LacZ is acquired through fusion of MPs (n = 2500--4,100 myofibers from 3--5 independent mice). In the quantification of (**B**), the control bars are from [Figure 1C](#fig1){ref-type="fig"}. (**C**) To genetically assess the requirement of myofiber-derived myomaker, tamoxifen was administered to *Tmem8c^LacZ/loxP^; ACTA1*^CreERT2^ mice (myomaker mKO) prior to MOV. qPCR analysis of myomaker in control, myomaker scKO, and myomaker mKO mice after MOV shows that myomaker is only reduced in myomaker scKO mice, demonstrating that myomaker is not transcribed from a myofiber nucleus (n = 3--4 mice). Data are represented as mean ± SEM, **\***p\<0.05. Scale bar: 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.20007.005](10.7554/eLife.20007.005)10.7554/eLife.20007.006Figure 2---figure supplement 1.Schematic showing the mice used to ablate myomaker in satellite cells, and their associated control groups.**DOI:** [http://dx.doi.org/10.7554/eLife.20007.006](10.7554/eLife.20007.006)10.7554/eLife.20007.007Figure 2---figure supplement 2.Myogenic progenitors are maintained in myomaker scKO muscle during MOV.(**A**) Flow cytometry for mGFP^+^ progenitors in tamoxifen-treated *Pax7*^CreERT2/+^; *Rosa*^mTmG^ (control) and *Tmem8c*^LacZ/loxP^; *Pax7*^CreERT2/+^; *Rosa*^mTmG^ mice (myomaker scKO) reveals a distinct GFP^-^ (red) and GFP^+^ (green) population of cells 7 and 10 days after MOV. Top panels reveal gating strategy derived from forward and side scatter plots. Plots shown are representative from one experiment. Quantitative analysis confirms similar levels of mGFP^+^ cells between control and myomaker scKO muscles at 7 and 10d of MOV (n = 3 for each group), indicating that myogenic progenitors are present after satellite cell ablation of myomaker. (**B**) Representative images of Pax7^+^ nuclei in plantaris sections further reveal that satellite cells are present in fusion-incompetent muscles throughout two weeks of MOV. Quantification revealed a significant difference 7 days after MOV when Pax7^+^ cells are analyzed per section but not when normalized to fiber number (n = 4--6). Data are represented as mean ± SEM, **\***p\<0.05. Scale bar: 10 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.20007.007](10.7554/eLife.20007.007)10.7554/eLife.20007.008Figure 2---figure supplement 3.Myomaker expression is reduced in myomaker mKO mice when tamoxifen is present concominant with satellite cell activation suggesting *ACTA1*^CreERT2^ is active in myoblasts prior to fusion (n = 3--4 mice).These data indicate the *ACTA1*^CreERT2^ transgene is functional. Data are represented as mean ± SEM, \*p\<0.05.**DOI:** [http://dx.doi.org/10.7554/eLife.20007.008](10.7554/eLife.20007.008)

We next assessed how the loss of myomaker in MPs impacts LacZ^+^ activity within the muscle. X-gal staining of plantaris sections from myomaker scKO mice after MOV demonstrates that myomaker expression is restricted to non-myofibers ([Figure 2B](#fig2){ref-type="fig"}). Quantification of LacZ^+^ non-myofibers revealed an accumulation at 7 days post-MOV in myomaker scKO mice compared to control mice, reflecting the inability of myomaker-deficient MPs to fuse to myofibers ([Figure 2B](#fig2){ref-type="fig"}). We also observed a lack of LacZ activity in myofibers in myomaker scKO mice at days 7--14 of MOV, suggesting that LacZ in myofibers in control mice is contributed through fusion of MPs ([Figure 2B](#fig2){ref-type="fig"}). Overall, these data indicate that myomaker is not actively transcribed from a myofiber nucleus in response to MOV.

One possibility for the lack of myonuclear transcription in myomaker scKO mice is that the myofiber requires expression of myomaker on MPs to activate myomaker transcription within the myofiber. To exclude this possibility, we genetically deleted myomaker using a myofiber-specific Cre and assessed myomaker levels after MOV. Specifically, we crossed *Tmem8c*^LacZ/loxP^ mice with a tamoxifen-inducible Cre under control of the human skeletal actin promoter (*ACTA1*^CreERT2^). We treated *Tmem8c*^LacZ/loxP^; *ACTA1*^CreERT2^ mice with tamoxifen (myomaker mKO) for 5 days prior to MOV and analyzed myomaker transcript levels through qPCR analysis. If myomaker was transcribed from a myofiber nucleus in the presence of WT MPs, we would expect a reduction of myomaker levels in myomaker mKO muscle after MOV. However, myomaker mKO MOV plantaris did not exhibit a reduction in myomaker levels compared to control MOV, whereas a reduction was achieved in myomaker scKO MOV plantaris ([Figure 2C](#fig2){ref-type="fig"}).

To be certain the *ACTA1*^CreERT2^ was functional, we assessed myomaker levels in myomaker mKO mice when tamoxifen delivery was maintained after MOV. Using this protocol, we did detect a reduction of myomaker expression in myomaker mKO mice, suggesting a functional *ACTA1*^CreERT2^ allele ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"}). Myomaker deletion in myomaker mKO mice was achieved only with maintenance of tamoxifen after MOV, likely because the human skeletal actin (*ACTA1*) promoter is activated as MPs differentiate and prior to fusion. Taken together, our results suggest the LacZ expression observed in control myofibers is acquired primarily from LacZ^+^ MPs through fusion, and not from transcription by existing myofiber nuclei. Hence, myomaker is activated mainly in MPs during muscle overload.

Satellite cell-derived myomaker is required for overload-induced muscle hypertrophy {#s2-3}
-----------------------------------------------------------------------------------

Since myomaker is mainly activated in MPs during MOV, we utilized myomaker scKO mice to determine the role of myomaker during hypertrophy. To ensure effective deletion of myomaker, control and myomaker scKO mice were subjected to five daily doses of tamoxifen prior to MOV, and kept on a tamoxifen regimen until sacrifice ([Figure 3A](#fig3){ref-type="fig"}). Following 14 days of overload, evaluation of plantaris weight normalized to tibia length revealed a two-fold increase in control MOV compared to sham ([Figure 3B](#fig3){ref-type="fig"}). In contrast, myomaker scKO MOV plantaris was smaller than control MOV, although still increased above myomaker scKO sham weight ([Figure 3B](#fig3){ref-type="fig"}). Muscle responds to a load-induced stimulus by generating new myofibers and activating hypertrophic pathways in existing myofibers. Indeed, through histological examination of the plantaris after MOV, in control mice we observed an increase in myofiber size, a more direct evaluation of hypertrophy ([Figure 3C](#fig3){ref-type="fig"}). This characteristic was not observed in myomaker scKO MOV plantaris sections, highlighting the importance of myomaker on MPs for efficient hypertrophy ([Figure 3C](#fig3){ref-type="fig"}). Cross-sectional area (CSA) analysis of fiber size revealed an increase in control MOV compared to control sham ([Figure 3C](#fig3){ref-type="fig"}). In contrast, no differences were detected between myomaker scKO sham and MOV, indicating defective myofiber hypertrophy following MOV with genetic deletion of myomaker in MPs ([Figure 3C](#fig3){ref-type="fig"}). In addition, frequency distribution analysis confirms the presence of fewer large myofibers in myomaker scKO muscles after overload ([Figure 3C](#fig3){ref-type="fig"}). Given that skeletal muscle is comprised of multiple different fiber types that have the capacity to dynamically adapt in response to physiological stimuli, we assessed if all fiber types were resistant to hypertrophy after loss of myomaker in SCs. We immunostained sections after 14 days of MOV with antibodies specific to Type I, Type IIa, and Type IIb myosin and quantified myofiber CSA for each fiber type. This analysis revealed no differences in fiber type frequency after MOV, and that genetic ablation of myomaker in SCs resulted in a lack of hypertrophy of Type IIa, IIb, and IIx myofibers ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).10.7554/eLife.20007.009Figure 3.Genetic loss of myomaker in MPs results in an absence of muscle hypertrophy.(**A**) Schematic showing timing of tamoxifen treatment by intraperitoneal (IP) injections, MOV, and tissue harvest. Tamoxifen was maintained after MOV through IP injections every other day. (**B**) Plantaris weight normalized to tibia length indicates a dramatic increase in size in control mice, which is blunted in myomaker scKO mice (n = 7--13 mice). (**C**) Representative laminin-stained plantaris sections shows an increase in myofiber size after muscle overload in control mice but not in myomaker scKO mice. Quantification of cross-sectional area (CSA) of myofibers at the plantaris mid-belly reveals a significant inhibition of myofiber hypertrophy with satellite cell ablation of myomaker (n = 3200--5,400 myofibers from 7--11 independent mice). Relative frequency of myofiber sizes in the various groups of mice demonstrates that control muscle exhibits a greater percentage of larger fibers after MOV. (**D**) Fiber number was quantitated at the mid-belly of the plantaris, and reveals a significant inhibition of new fiber formation in plantaris muscle when myomaker was ablated in satellite cells (n = 7--11 mice). Data are represented as mean ± SEM, **\***p\<0.05. Scale bar: 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.20007.009](10.7554/eLife.20007.009)10.7554/eLife.20007.010Figure 3---figure supplement 1.All fiber types fail to hypertrophy in myomaker scKO muscle after MOV.Representative plantaris sections immunostained with antibodies for laminin, myh7 (Type I myosin, red), myh2 (Type IIa, yellow), and myh4 (Type IIb, green). Type IIx fibers are unstained. Quantification of fiber type cross-sectional area at the plantaris mid-belly reveals a significant increase in Types IIa, IIb, and IIx myofiber size in control mice after overload, whereas myofiber hypertrophy in each of these fiber types is significantly inhibited with satellite cell ablation of myomaker (n = 28--54 fibers (Type I) or 500--1,900 fibers (Types IIa, IIb, IIx) from 3--5 independent mice). Frequency distribution analysis reveals that fiber type composition remains relatively unaltered after 14 days of MOV (n = 1100--1,700 fibers from three independent mice). Data are represented as mean ± SEM, **\***p\<0.05. Scale bar: 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.20007.010](10.7554/eLife.20007.010)

Furthermore, the total number of fibers is elevated in control MOV compared to control sham mice, but fiber number is similar between sham and overloaded muscles in myomaker scKO mice ([Figure 3D](#fig3){ref-type="fig"}). These data suggest an inability of myomaker-deficient MPs to fuse to each other to generate de novo myofibers, indicating a distinct requirement for myomaker in augmenting fiber number during the response to overload. The blunted hypertrophic phenotype observed in myomaker scKO mice can therefore be attributed to an impairment in hypertrophy of existing myofibers and a failure to generate de novo fibers following overload. Collectively, our findings demonstrate the requirement of satellite cell-derived myomaker for load-induced adult skeletal muscle hypertrophy.

Fusion during MOV is blocked through deletion of myomaker in SCs {#s2-4}
----------------------------------------------------------------

We utilized two independent approaches to determine whether the diminished hypertrophic response to overload in myomaker scKO mice is associated with deficits in MP fusion. First, mice were administered daily dosages of BrdU post-surgery throughout the entire duration of MOV while maintaining the tamoxifen regimen ([Figure 4A](#fig4){ref-type="fig"}). As described above, BrdU labels proliferating cells (including MPs) and fusion was assayed by tracking the incorporation of a BrdU^+^ nucleus into a dystrophin^+^ myofiber. After 14 days of overload in control mice, BrdU^+^ nuclei within a dystrophin-stained myofiber were readily detected ([Figure 4B](#fig4){ref-type="fig"}). In comparison, BrdU^+^ nuclei reside primarily in the interstitium between myofibers in overloaded myomaker scKO mice, indicating efficient abrogation of fusion ([Figure 4B](#fig4){ref-type="fig"}). Indeed, quantification of the percentage of BrdU^+^ myofibers revealed \~30% of myofibers in control mice underwent a fusion event, however in myomaker scKO mice BrdU^+^ myofibers are at basal levels observed in shams ([Figure 4B](#fig4){ref-type="fig"}). Given that this is one level of a muscle, if a BrdU myonucleus was above or below this plane then that fiber would not be counted as a positive fusion event. Therefore, this BrdU analysis may underestimate the extent of fusion that occurs during MOV.10.7554/eLife.20007.011Figure 4.Myomaker is required for fusion during overload-induced muscle hypertrophy.(**A**) Schematic showing treatment with tamoxifen and BrdU. (**B**) Representative images of BrdU^+^ nuclei within a dystrophin-stained myofiber (arrows) indicating fusion. In myomaker scKO mice, BrdU^+^ nuclei were observed only in the interstitium between myofibers. Quantification of the percentage of BrdU^+^ myofibers shows that 30% of fibers undergo fusion in control samples after MOV while this is dramatically reduced in myomaker scKO mice (n \> 300 fibers from three independent mice). (**C**) *Tmem8c^LacZ/loxP^; Pax7^CreERT2/+^* were crossed with *Rosa^mTmG^* mice to genetically assay fusion. Tamoxifen-treated *Tmem8c^+/+^; Pax7^CreERT2/+^; Rosa^mTmG^* mice were used as controls. Upon tamoxifen treatment, SCs will be converted from mTomato-expressing to mGFP-expressing. mGFP^+^ myofibers indicates fusion with MPs. (**D**) In sham mice, only minimal mGFP^+^ fibers were observed. Control MOV mice display numerous mGFP^+^ myofibers, indicating the majority of myofibers undergo a fusion event. Myomaker scKO mice exhibited marginal mGFP^+^ fibers (n = 4 mice). (**E**) Single fibers were isolated from control and myomaker scKO mice and analyzed for mTomato and mGFP expression. Quantification of mGFP intensity in single fibers shows an increase in control MOV, which is inhibited when myomaker is ablated in satellite cells (n = 90--120 myofibers from 3--4 independent mice). Data are represented as mean ± SEM, **\***p\<0.05. Scale bars: 50 μm, except insets in (**B**) which are 25 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.20007.011](10.7554/eLife.20007.011)

To complement our BrdU assay and establish greater insight into the magnitude of fusion during physiological hypertrophy, we used a fluorescent genetic reporter that offers enhanced sensitivity in detecting fusion events. Specifically, *Tmem8c^+^*^/+^; *Pax7*^CreERT2/+^; *Rosa26*^mTmG^ mice (controls) and *Tmem8c*^LacZ/loxP^; *Pax7*^CreERT2/+^; *Rosa26*^mTmG^ (myomaker scKO) mice were treated with tamoxifen to induce expression of mGFP in MPs ([Figure 4C](#fig4){ref-type="fig"}). With this strategy, existing myofibers will maintain mTom expression and also be mGFP^+^ if they have fused with MPs, while myofibers that are solely mGFP^+^ would represent de novo myofibers arising from the fusion of MPs with each other. After muscle overload the majority of existing myofibers in control mice undergo fusion with MPs, evaluated by expression of both mTom and mGFP, which was not observed in overloaded myofibers of myomaker scKO mice ([Figure 4D](#fig4){ref-type="fig"}). To quantify fusion in this genetic model, we isolated single myofibers and analyzed their relative mGFP intensity normalized to total fiber area using ImageJ ([Figure 4E](#fig4){ref-type="fig"}). Here, we detected a significant increase in mGFP intensity of single fibers in control mice after overload, which is reduced to sham levels after genetic ablation of myomaker in MPs ([Figure 4E](#fig4){ref-type="fig"}). Our overall findings substantiate that expansive MP fusion occurs during load-induced skeletal muscle hypertrophy, and that myomaker expression on MPs is essential for this myogenic process. Moreover, these results indicate that myomaker-mediated fusion is necessary for myofiber hypertrophy in response to physiological stimuli.

Altered muscle signaling and fibrosis in fusion-incompetent muscle during hypertrophy {#s2-5}
-------------------------------------------------------------------------------------

An established mechanism for eliciting muscle hypertrophy is through the Akt1 pathway, which activates mTOR and p70s6k and ultimately leads to enhanced protein synthesis ([@bib9]). We explored how this pathway is perturbed with defective MP fusion during adult muscle hypertrophy. To this end, western blot analysis revealed an expected increase in phosphorylated levels of Akt (Ser473) and p70s6k (Thr389) in control MOV muscles at 7 and 14 days of overload ([Figure 5A](#fig5){ref-type="fig"}). Activation of these pathways was significantly blunted in myomaker scKO overload muscle, highlighting a mechanism by which myomaker expression on MPs regulates hypertrophy ([Figure 5A](#fig5){ref-type="fig"}). Additionally, total levels of p70s6k were elevated in control MOV muscles compared to myomaker scKO overload muscles, which could be indicative of enhanced overall protein translation in control MOV samples during hypertrophy ([@bib2]). Quantitative analysis of normalized pAkt and p-p70s6k levels further demonstrates significant disruptions in the Akt/mTOR pathway in fusion-incompetent muscles subjected to overload ([Figure 5A](#fig5){ref-type="fig"}).10.7554/eLife.20007.012Figure 5.Hypertrophic signaling pathways are reduced in the absence of fusion during MOV.(**A**) Western analysis for pAkt (Ser473), total Akt, p-p70^S6K^ (Thr389), and total p70^S6K^. Control plantaris muscle displays pAkt and p-p70^S6K^ activation after MOV compared to sham controls, however the pathways are not fully activated in myomaker scKO MOV muscles. Quantification of the western signal obtained for pAkt normalized to total protein, and quantification of the western signal obtained for p-p70^S6K^ normalized to total protein both reveal altered Akt/mTOR signaling in myomaker scKO muscles after MOV (n = 4 mice). (**B**) Analysis of protein synthesis through puromycin incorporation into nascent peptides. Mice were injected with puromycin and sacrificed thirty minutes later. Sections were then immunostained with antibodies to puromycin and myh3, a marker of newly generated muscle cells. Puromycin staining is increased in both myh3^+^ myofibers (de novo, arrowhead) and myh3^-^ myofibers (existing, arrow) in control samples after MOV. Only myh3^-^ myofibers were observed at 14 days of MOV. Quantification revealed significantly more puromycin incorporation in myh3^-^ myofibers in control samples at both 7 and 14 days after MOV compared to myomaker scKO MOV muscles (2200--3400 fibers from n = 3--4 independent mice). Data are represented as mean ± SEM, **\***p\<0.05. Scale bar: 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.20007.012](10.7554/eLife.20007.012)

The ultimate function of mTOR signaling is to activate protein synthesis in myofibers for hypertrophy, therefore we directly investigated rates of protein synthesis after MOV using a technique by which puromycin is incorporated into nascent polypeptides, and is thus a readout of active protein synthesis ([@bib38]). We injected puromycin into control and myomaker scKO mice thirty minutes prior to sacrifice and assayed for puromycin incorporation into myofibers through immunostaining of muscle sections with a puromycin antibody ([@bib14]). We also co-immunostained these sections with embryonic myosin (myh3) to evaluate the relative contribution of protein synthesis from de novo and existing myofibers. We observed minimal puromycin in sham samples, however in control muscle puromycin was elevated in both myh3^-^ (existing) and myh3^+^ (de novo) myofibers 7 days after MOV ([Figure 5B](#fig5){ref-type="fig"}). At 14 days of MOV, we detected minimal myh3^+^ myofibers although puromycin remained elevated in existing fibers of control mice, whereas myomaker scKO muscle did not exhibit significant puromycin incorporation at either time point analyzed ([Figure 5B](#fig5){ref-type="fig"}). Of note, we did not observe myh3^+^ cells in myomaker scKO muscle 7 days after MOV, further demonstrating that myomaker is required to form new myofibers ([Figure 5B](#fig5){ref-type="fig"}). Given that myh3^+^ myofibers are not present in myomaker scKO muscle we only quantified the puromycin intensity in myh3^-^ myofibers, which revealed a significant inability for fusion-incompetent muscle to activate protein synthesis ([Figure 5B](#fig5){ref-type="fig"}). Our findings indicate that SC-derived myomaker is required for full activation of Akt/mTOR signaling and protein synthesis in the myofiber, which could serve as a potential mechanism though which fusion drives the hypertrophic response.

In addition to the activation of signaling pathways to achieve optimal hypertrophy, muscle hypertrophy is also associated with remodeling of extracellular matrix (ECM) content. While the mechanisms that govern ECM alterations during muscle hypertrophy and regeneration are relatively unknown, one aspect of this regulation is dependent on the presence of MPs ([@bib12], [@bib13]; [@bib32]). Thus, we sought to determine the consequence on ECM in fusion-defective muscle that is sensing increased load. We performed Masson's Trichrome staining on control and myomaker scKO sham and MOV muscle, which revealed modest fibrosis in control MOV, indicating that ECM remodeling is a normal process for hypertrophy ([Figure 6](#fig6){ref-type="fig"}). In contrast, we observed an increase in fibrosis in the overloaded muscles of myomaker scKO mice ([Figure 6](#fig6){ref-type="fig"}). Quantification of the fibrotic area indeed revealed a significant increase in fibrosis in myomaker scKO samples ([Figure 6](#fig6){ref-type="fig"}). Consequently, the enhanced accumulation of ECM in myomaker scKO MOV muscle may explain the increase in muscle weight despite the lack of myofiber hypertrophy ([Figure 3](#fig3){ref-type="fig"}). This non-functional gain in muscle size illustrates that in place of de novo and larger myofibers, there is an increased formation of connective tissue in muscles with non-fused MPs, suggesting a protective role for fusion in stabilizing muscle architecture associated with increased workload.10.7554/eLife.20007.013Figure 6.Loss of myomaker in satellite cells results in increased fibrosis during physiological hypertrophy.Trichrome stained sections from control and myomaker scKO mice demonstrate a significant increase in fibrosis in myomaker scKO mice after MOV. Quantification of the fibrotic area further demonstrates increased fibrosis in fusion-incompetent muscle. Values indicate mean (n = 4--12 mice) ± SEM, **\***p\<0.05. Scale bar: 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.20007.013](10.7554/eLife.20007.013)

Discussion {#s3}
==========

Skeletal muscle hypertrophy is a highly desirable adaptation of various therapeutic strategies to restore strength and function in muscle wasting conditions. Functional gains in adult muscle mass are derived from elevations in protein synthesis within the myofiber, and our findings highlight an additional source for muscle hypertrophy through the contributions of muscle stem cell fusion. Specifically, we use BrdU labeling and genetic lineage tracing approaches to evaluate the extent of fusion during overload-induced hypertrophy. While BrdU analysis revealed approximately 30% of fibers to undergo a fusion event, findings from the fluorescent reporter model demonstrate that the majority of myofibers fuse (mGFP^+^), indicating the BrdU strategy is an underestimation of the fusion process during muscle hypertrophy. We also reveal that in response to increased muscle workload, myomaker is primarily upregulated in activated SCs, which is required for fusion with a myofiber. In the absence of SC-derived myomaker, the activation of pro-hypertrophic signaling pathways and protein synthesis, and increases in myofiber size and number are diminished. Thus, myomaker-mediated fusion is required for load-induced hypertrophy of skeletal muscle.

The requirement of muscle stem cells during adult skeletal muscle hypertrophy has long been a source of debate. Indeed, blunting of hypertrophy was observed after elimination of satellite cells through gamma irradiation ([@bib1]) or through genetic manipulation of IL-6-dependent effects on SC/MP activity ([@bib15]; [@bib40]). However, two independent groups utilized DTA-mediated ablation of SCs and produced widely contrasting results. The initial SC DTA experiments indicated that SCs are not necessary for hypertrophy, where CSA was increased 10% in control mice with normal SC activity. ([@bib12]; [@bib27]). In contrast, a recent report also using ablation of SCs through DTA provides evidence that muscles fail to undergo overload-induced hypertrophy in the absence of SCs, and this study reported a 26% increase of CSA in control mice ([@bib10]). While the interpretation of these two studies are vastly different, the magnitude of hypertrophy achieved, which is best assessed through CSA analysis and not gross muscle weights, is not similar and may account for the divergent outcomes. The magnitude of CSA increase in our study was 29% in control mice after MOV, which is more similar to the work by Egner et al. We also observed an approximate 10% CSA increase in myomaker scKO MOV samples compared to myomaker scKO sham. Although this increase was not significant it suggests that myofibers harbor a minor hypertrophic potential in the absence of fusion consistent with Fry et al. Through generation of fusion-defective SCs however, we provide independent evidence for the necessity of SCs for any major muscle hypertrophy.

While our findings demonstrate that fusion during muscle overload is inhibited by loss of myomaker in SCs, the exact contribution of fusion for hypertrophy remains to be elucidated. During compensatory hypertrophy, newly acquired myonuclei precede muscle hypertrophy ([@bib5]). Thus, fusion may provide new nuclei to facilitate enhanced transcription of contractile proteins necessary for hypertrophy, as supported by our findings that myofibers are not able to activate protein synthesis in the absence of fusion. Addition of a new nucleus to the myofiber may also function to maintain a constant myonuclear domain ([@bib31]), however this concept has been challenged especially during postnatal muscle development ([@bib46]). Alternatively, fusion may not only provide new nuclei but also other factors necessary for hypertrophy, such as ribosomes for protein translation, or a bolus of signaling molecules to activate hypertrophic pathways similar to the activation of Akt by Wnt7a ([@bib45]). These concepts clearly require more extensive work to reveal definitive mechanisms through which SC fusion drives adult skeletal muscle hypertrophy.

The Akt/mTOR pathway is controlled by insulin-like hypertrophy factor 1 (IGF-1) and myostatin, a member of the transforming growth factor-β (TGF-β). IGF-1 directly activates the Akt pathway ([@bib35]) while myostatin is a negative regulator of muscle mass through SMAD-dependent inhibition of Akt ([@bib37]; [@bib44]). The inability for muscle to initiate Akt/mTOR signaling without myomaker expression in myogenic progenitors was surprising since previous studies have shown that myofibers have the ability to intrinsically activate this canonical protein synthesis pathway ([@bib4]; [@bib22]). Indeed, SC activation is not observed during muscle hypertrophy induced through a constitutively active Akt transgene ([@bib3]), or inhibition of myostatin action by pharmacological blockade of its receptor ACVR2B ([@bib23]). It is conceivable that during overload-induced hypertrophy, the increased tension placed on the myofiber requires SC-mediated activity for hypertrophy, whereas there is an absence of mechanical strain on the myofiber through treatment with IGF-1 or ACVR2B antibody. The ultimate goal of muscle hypertrophy is to increase contractile capability to deal with heightened physiological demands. Hypertrophy associated with loss of myostatin may not yield long-term improvements in muscle function suggesting that addition of myonuclei are necessary for functional hypertrophic gains ([@bib16]). We did not assess muscle contractile function in our fusion-defective mice after MOV, however this will be important to fully elucidate the physiological relevance for MP fusion during muscle hypertrophy.

Our finding of increased fibrosis in muscles of myomaker scKO mice after overload further suggests a protective role for SC fusion on myofiber stability in response to mechanical strain, however the cellular circuitry driving fibrosis development remains unknown. DTA-mediated deletion of SCs also results in increased ECM components during overload-induced hypertrophy and aging, potentially through lack of interactions between SCs and fibroblasts ([@bib12]; [@bib19]; [@bib32]). Indeed, recent work suggests that the main function of MPs during overload-induced hypertrophy is to release miR-206-containing exosomes that dampen collagen production in fibroblasts, and that loss of MPs facilitates development of fibrosis ([@bib11]). After overload of myomaker scKO mice, MPs are still present in muscle, suggesting the major reason for fibrosis can be attributed to an inability to maintain myofiber integrity due to loss of SC activity. It is formally possible that MPs lacking myomaker are not only fusion-defective but also lack an ability to communicate with fibroblasts through paracrine signaling. However, given that no evidence exists supporting this possibility, and that we observed significant fusion during MOV, our data are more consistent with a model where fibrosis occurs in myomaker scKO MOV muscles due to an inability to repair myofiber mechanical strain. This model of myofiber mechanical strain eliciting fibrosis is not unlike what occurs in other contexts, such as in cardiac muscle subjected to pressure overload where fibrosis functions to maintain tissue architecture ([@bib7]; [@bib43]).

One intriguing question to arise from this study pertains to the fate of fusion-incompetent MPs. Compared to control, we observed an increase in the number of LacZ^+^ cells (MPs) in myomaker scKO muscle at day 7 after MOV. These data could indicate an accumulation of MPs because they have not fused. However, 10 days after MOV the number of LacZ^+^ cells was comparable between control and myomaker scKO muscle, suggesting that accumulated LacZ^+^ fusion-defective cells die between day 7 and day 10 of MOV or that myomaker is down-regulated and they become LacZ^-^. Analysis of MPs using a genetic reporter (mGFP) found no dramatic difference in the percentage of mGFP^+^ cells between control and myomaker scKO MOV samples. These inconsistencies highlight the current lack of knowledge regarding fusion-defective MPs. It is possible that the LacZ^+^ cells represent a small fraction of MPs and not enough to shift the percentage of mGFP^+^ MPs analyzed through flow cytometry. Also, since mGFP^+^ MPs are expressed as a percentage of the total cell population, changes in non-MP populations could indirectly alter the mGFP^+^ percentage. Nonetheless, the behavior and fate of fusion-incompetent MPs requires future investigation.

In conclusion, we have shown that myomaker is activated on SCs allowing fusion with a myofiber during muscle hypertrophy, thereby promoting hypertrophic signaling pathways and minimizing fibrosis associated with mechanical strain. These findings modify current theories for the role of muscle stem cells during hypertrophy and may lead to new intervention strategies for muscle wasting diseases.

Materials and methods {#s4}
=====================

Animals {#s4-1}
-------

The generation of myomaker mouse strains used in this study was described previously ([@bib30]). Briefly, *Tmem8c*^LacZ/+^ mice contain a LacZ cassette in intron 1 of the myomaker locus. *Tmem8c*^loxP/+^ mice contain loxP sites that flank exon 2. *Tmem8c*^LacZ/loxP^ mice were then bred with mice carrying the satellite cell-specific (*Pax7*^CreERT2^) ([@bib24]) or myofiber-specific (*ACTA1*^CreERT2^) ([@bib39]) Cre recombinase. To assess fusion, *Tmem8c*^+/+^; *Pax7*^CreERT2/+^ mice (control) and *Tmem8c*^LacZ/loxP^; *Pax7*^CreERT2/+^ mice (myomaker scKO) were crossed with *Rosa26*^mTmG^ mice (Jackson Laboratory \# 007676). Experimental mice were at least 3 months of age prior to any procedure performed. All animal procedures were approved by Cincinnati Children's Hospital Medical Center's Institutional Animal Care and Use Committee.

Tamoxifen and BrdU {#s4-2}
------------------

Tamoxifen (TAM; Sigma-Aldrich) was mixed in corn oil with 10% ethanol at 25 mg/ml. Prior to muscle overload surgery, 3-month old mice were administered five daily doses of TAM at 0.075 mg/g/day through intraperitoneal injections. Following surgery, mice were maintained on a TAM regimen (with the exception of mice used in [Figure 2C](#fig2){ref-type="fig"}) throughout MOV and administered 10 μl/g BrdU (Thermo Fisher Scientific) as indicated. No statistical differences in body weights were observed after tamoxifen treatment in either control or *myomaker*^scKO^ mice.

Synergist ablation {#s4-3}
------------------

Muscle overload of the plantaris muscles was achieved through bilateral synergistic ablation of soleus and gastrocnemius muscles as described by others ([@bib8]). Briefly, the soleus and gastrocnemius muscles were exposed by making an incision on the posterior-lateral aspect of the lower limb. The distal and proximal tendons of the soleus were cut followed by cutting of the distal gastrocnemius tendon and excision of 75% lateral and medial gastrocnemius.

Muscle collection and preparation {#s4-4}
---------------------------------

Plantaris muscles were dissected, blotted dry, and weighed. Hindlimbs were dissected and dissolved overnight in lysis buffer containing 0.4 mg/ml proteinase K at 55°C. Tibia length was assessed by a digital caliper, and the average of three measurements was recorded. For cryosections, muscles were embedded in 1% tragacanth/PBS (Sigma), and frozen in liquid nitrogen-cooled 2-methylbutane. Sections were then cut at 10 μm. For gene and protein analysis, mice were fasted for four hours, and muscles were flash-frozen in liquid nitrogen and stored at −80°C. For *Tmem8c*^LacZ/loxp^; *Pax7*^CreERT2/+^; *Rosa26*^mTmG^ mice, plantaris muscles were fixed in 4% PFA/PBS for 5 hr at 4°C and sucrose protected overnight (30% sucrose/PBS) followed by embedding and cryosectioning.

X-gal staining {#s4-5}
--------------

Cryosections were stained with X-gal as described previously ([@bib30]). After staining, the samples were rinsed in PBS and fixed in 4% PFA/PBS for at least 10 min. Tissue sections were co-stained with light eosin (0.7%), dehydrated, and mounted with Permount (Fisher). Samples were visualized on an inverted bright-field microscope (Olympus BX51), and the numbers of LacZ^+^ non-myofibers, LacZ^+^ myofibers, and all myofibers in a given field of view were manually counted. Data presented is representative of the average number of LacZ^+^ non-myofibers, and the percentage of LacZ-expressing myofibers, quantified from several non-overlapping fields of view.

Muscle progenitor isolation and flow cytometry {#s4-6}
----------------------------------------------

We isolated skeletal muscle stem cells using techniques described previously ([@bib26]). Briefly, plantaris muscles from either tamoxifen-treated *Tmem8c^+/+^; Pax7*^CreERT2/+^; *Rosa26^mTmG^* or *Tmem8c^LacZ/lox^*^p^; *Pax7*^CreERT2/+^; *Rosa26^mTmG^* mice were collected and minced in 10% horse serum (HS) (Gibco \# 26050--070), and then incubated in 800 U/ml Collagenase Type 2 (Worthington \# CLS-2) solution at 37°C with gentle agitation for 1 hr. Following centrifugation, pellets were resuspended in 10% HS with 1000 U/ml Collagenase Type II and 4.8 U/ml Dispase (Roche \# 4942078001), and incubated at 37°C with gentle agitation for another 30 min. Following this second round of incubation, samples were triturated with a 20-gauge needle, centrifuged and resuspended in 10% HS. Cell suspensions were subsequently filtered through a 40 μm nylon cell strainer (Corning \# 352340), centrifuged, and resuspended in 2% Fetal Bovine Serum/PBS (Hyclone \# SH30071). Flow cytometry analysis on cell suspensions was performed with a BD Biosciences LSR II Flow Cytometer configured with the 488 nm laser for GFP and the 561 nm laser for Tomato. Voltages were determined using cell suspensions from vehicle-treated *Tmem8c*^+/+^; *Pax7*^CreERT2/+^ and *Tmem8c^+/+^; Pax7*^CreERT2/+^; *Rosa26^mTmG^* mice. Analysis was performed using FACSDiva software.

Histological analyses {#s4-7}
---------------------

Cryosections were fixed in 1% PFA/PBS; permeabilized with 0.2% Triton X-100/PBS or denatured with 2 M HCL in 0.5%Triton X-100/PBS and subsequently neutralized with TBS (pH 8.4) for BrdU labeling. After neutralization, sections were blocked with 1% BSA, 1% heat-inactivated goat serum, and 0.025% Tween20/PBS; and incubated with primary antibody overnight at 4°C. Following 1 hr of incubation with a secondary Alexa Fluor antibody (1:200) (Invitrogen), slides were mounted with VectaShield containing DAPI (Vector Laboratories). For assessment of hypertrophy, samples were stained with anti-laminin (1:100; Sigma-Aldrich \# L9393), and representative non-overlapping images from all sections were captured at 20x on a Nikon A1R confocal system. The cross-sectional area (CSA) of myofibers was quantified through a binary thresholding algorithm developed in Imaris (Bitplane). Whole section images were also taken at 10x, and the total number of myofibers per muscle section was determined through an automated image segmentation program from ImageJ. To assay for fusion, samples were co-stained with anti-BrdU (1:20; Roche \#11170376001) and anti-dystrophin (1:100; Abcam \#ab15277). The following antibodies from Developmental Studies Hybridoma Bank were also used: Pax7 (1:50), myh7 (1:100; clone BA-D5), myh2 (1:100; clone SC-71), myh4 (1:10; clone BF-F3), and myh3 (1:10; clone F1.652). For Pax7 immunostaining, the above protocol was used in addition to antigen retrieval (1x Antigen Retrieval Citra Solution (Biogene \# HK086-9K) and boiled for 30 min), followed by incubation with Pax 7antibodies overnight. The following day, 1:200 M.O.M. biotinylated anti-mouse IgG (Vecta Laboratories) was incubated for 30 min, washed, and then 1:200 Strepdavidin-Alexa Fluor 488 (Invitrogen) was incubated for 30 min. All samples were visualized at 40x with a Nikon A1R+ LUNV on a Ti-E Inverted Microscope unless otherwise noted. For mTom/mGFP analysis, sucrose-protected samples were visualized at 10x. The authenticity of mGFP signal was verified by establishing baseline levels for auto-fluorescence in vehicle-treated mice (GFP^-^). Masson's Trichrome staining was performed using standard protocols, and total fibrotic area within a section was quantified with a threshold intensity program from ImageJ.

Single fiber isolation {#s4-8}
----------------------

To quantify overall mGFP^+^ expression, single fibers were isolated from plantaris muscles of sham and overloaded mice, as described previously ([@bib20]). Whole plantaris muscles were incubated in 0.2% Type I collagenase (Sigma-Aldrich, \# C-0130) for 1 hr at 37°C. Muscles were transferred to DMEM (Hyclone) containing 10% horse serum and triturated to release individual fibers. Fibers were then fixed in 4% PFA/PBS for 30 min at 4°C, washed three times in PBS, permeabilized and mounted with Vectashield containing DAPI, and visualized at 10x on a Nikon A1R confocal system. Identical settings were utilized to capture mGFP and mTomato fluorescent images from all fibers and then processed in ImageJ. Fibers isolated from vehicle-treated mice were used to establish an impartial baseline for auto-fluorescence, and the threshold for GFP intensity was set at a constant value. The absolute GFP intensity for individual experimental fibers was then determined by tabulating the integrated density of saturated pixels above threshold levels. Similarly, tomato expression was used to quantify myofiber area by calculating the total pixelated area above background. GFP intensity was then normalized to myofiber area.

In vivo assessment of protein synthesis {#s4-9}
---------------------------------------

Changes in protein synthesis in whole muscle cross-sections were detected through utilization of antibiotic puromycin, a non-radioactive technique known as surface sensing of translation (SUnSET) ([@bib14]; [@bib38]). Following 4 hr of fasting, mice were administered 0.04 μmol puromycin/gram of body weight dissolved in PBS intraperitoneally for 30 min, and plantaris muscles subsequently collected for cryosections. Sections were immunostained with anti-puromycin (1:1000; EMD Millipore; clone 12D10), and anti-embryonic myosin (myh3). For the purpose of defining the myofiber borders we also stained the sections with anti-laminin. Representative images were captured at 20x, and a binary algorithm developed in Imaris was used to calculate the mean puromycin intensity within a laminin-stained myofiber. Samples were automatically distinguished as myh3^+^ (de novo) or myh3^-^ (existing) myofibers within the same image, and puromycin intensities for individual myofibers in each group were quantified separately.

RNA analysis {#s4-10}
------------

Total RNA was extracted from plantaris muscle with Trizol (Invitrogen), and cDNA was synthesized using MultiScribe^TM^ reverse transcriptase with random hexamer primers (Applied Biosystems). Gene expression was assessed using standard qPCR approaches with PowerUp^TM^ SYBR Green Master Mix (Applied Biosystems). Analysis was performed on a 7900HT fast real-time PCR machine (Applied Biosystems) with the following myomaker SYBR primers: Forward, 5'-ATCGCTACCAAGAGGCGTT-3'; and Reverse, 5'-CACAGCACAGACAAACCAGG-3'. GAPDH primers (Forward, 5'-TGCGACTTCAACAGCAACTC-3'; and Reverse, 5'-GCCTCTCTTGCTCAGTGTCC-3\') were used as internal controls.

Western blot {#s4-11}
------------

A myomaker custom antibody was generated through YenZym Antibodies LLC. Rabbits were immunized with amino acids \#137--152 of mouse myomaker (MKEKKGLYPDKSIYTQ) after conjugation to KLH. We used antigen-specific affinity purified products for western analysis. Plantaris muscles were homogenized with a bead homogenizer (TissueLyser II; Qiagen) in a lysis buffer \[10 mM Tris (pH 7.4), 1 mM EDTA, 1 mM dithiothreitol, 0.5% Triton X-100, 2.1 mg/ml NaF\] containing protease and phosphatase inhibitor cocktails (5 μl/ml; Sigma-Aldrich), and following centrifugation, the amount of protein in supernatants was determined through Bradford protein assay. Muscle homogenates were heated at 65°C for 30 min, separated on 10% (30 μg of protein for detection of signaling proteins along the Akt/mTOR pathway) or 12% (100 μg of protein for myomaker detection) SDS-page gels, and transferred to PVDF-FL membranes (Immobilon). Membranes were subsequently blocked in 5% dry milk or 5% BSA in Tris-buffered saline (TBS)-Tween, and incubated overnight at 4°C with an antibody against myomaker (1:200), phosphorylated Akt (Ser473) (1:750; Cell Signaling \# 9271), total Akt (1:750; Cell Signaling \# 9272), phosphorylated p70s6k (Thr389) (1:500; Santa Cruz \# SC-11759), or total p70s6k (1:750; Cell Signaling \# 2708). GAPDH (1:5000; Millipore) served as a control for sample loading. Membranes were then washed and incubated with an IRDye 800CW anti-rabbit secondary antibody (1:5000; LI-COR Biosciences). The relative abundance of phosphorylated and total protein levels of Akt and p70s6k was quantified using the Odyssey infrared detection system (LI-COR Biosciences).

Statistical analysis {#s4-12}
--------------------

Quantitative data sets are presented as means ± SEM, and analyzed with an unpaired t-test ([Figures 1D](#fig1){ref-type="fig"} and [2A](#fig2){ref-type="fig"}), a one-way analysis of variance (ANOVA) ([Figures 1A, C](#fig1){ref-type="fig"} and [2C](#fig2){ref-type="fig"}), or a two-way ANOVA (all other data sets) using GraphPad Prism 6 software. For assessments of myofiber CSA, total fiber number, BrdU incorporation, single fiber fluorescent intensity, and levels of protein synthesis in myofibers both image captures and data analyses were performed in a blinded fashion. Statistical significance was set at a p value \<0.05.
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Thank you for submitting your article \"Requirement of myomaker-mediated stem cell fusion for skeletal muscle hypertrophy\" for consideration by *eLife*. Your article has been favorably evaluated by Sean Morrison (Senior Editor) and three reviewers, one of whom, Amy J Wagers (Reviewer \#1), is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Pax7^+^ Satellite cells (SCs) are resident muscle stem cells that are indispensable for adult skeletal muscle regeneration. Whether SCs are required for muscle fiber hypertrophy remains controversial. A previous study using Pax7-DTA alleles (*Pax7*^CreER/+^; *Rosa26*^DTA/+^) to deplete SCs showed no impact on subsequent fiber hypertrophy upon mechanical overload (MOV) despite a diminished increase of myonuclei (McCarthy et al. 2011). However, results from this study could have been confounded by incomplete SC ablation and/or by indirect effects of dying SCs.

Goh and Millay address this ongoing controversy from a new angle, by generating fusion-incompetent muscle progenitors via manipulation of expression of myomaker, a recently identified transmembrane protein necessary for myoblast fusion. The authors use state-of-the-art genetic systems, including conditional myomaker alleles to achieve SC-specific deletion of myomaker (myomaker^scKO^) in adult mice. They show that with these animals, in which SCs and their progeny are unable to fuse, overload-induced hypertrophy is blunted, indicating a role for SC fusion in mounting an optimal hypertrophic response. They substantiate this conclusion using additional BrdU molecular tracking and a color-switching genetic lineage tracing strategies, which further demonstrate the contribution and requirement of myomaker-mediated stem cell fusion for skeletal muscle hypertrophy. Finally, the authors provide data indicating a reduction of Akt signaling, a pathway known for eliciting muscle hypertrophy, in myomaker scKO MOV muscles following fusion-blockade (although this aspect of the work remains rather preliminary, see below).

Overall, the work has a number of strengths. Most importantly, the novel approach adopted by the authors to disable SC fusion without directly inducing cytotoxicity offers a fresh perspective to study the requirement of SCs for muscle hypertrophy. The experiments are well designed and conducted, and the arguments are reasonably supported. The genetic tools developed by the authors could be useful beyond the scope of this manuscript to the skeletal muscle field for studying the contribution of muscle stem cells fusion in other settings. There are however a number of issues related to the strength with which the authors\' data support the conclusions drawn and the presentation of these data that need to be addressed before publication.

Essential revisions:

1\) Ideally, the impact of fusion blockade by ablation of myomaker in muscle progenitor cells would be further supported by evaluation of muscle contractile function. This is important in order to establish the essential contribution of myomaker-mediated stem cell fusion during physiological muscle hypertrophy. Both whole-muscle and single-fiber function assays have been reported previously for MOV systems (Fry et al. 2014 FASEB journal), and inclusion of one of these types of analyses would greatly strengthen the paper. However, the reviewers recognize that these studies may prove difficult to complete in a timely fashion, and so, if the authors are unable to include them in a revised manuscript, they should instead add a comment to the paper\'s discussion indicating that such physiology studies will be important to evaluate in future studies.

2\) In [Figure 1C, D](#fig1){ref-type="fig"}, and E, how do the authors recognize mononuclear cells and fully differentiated myocytes? How do they distinguish the location of blue color in day 3, 7, 10 and 14 in [Figure 1C](#fig1){ref-type="fig"}? Lots of blue color appears inside cells, not on the membrane. Does this mean that myomaker is not a membrane protein in myotubes? These are critical points and should be explained and documented by clear experiments.

3\) The authors rely extensively on reporter gene expression and mRNA () to track Myomaker protein; however, as commercial antibodies are now available, they should confirm these data by direct staining for myomaker protein in SCs and myofibers.

4\) Analysis of co-localization of Pax7 and lacz^+^ in MOV model using the existing subsequent muscle sections is needed to evaluate if satellite cell homing/localization is affected in the hypertrophy model.

5\) There are multiple muscle fiber types present in the plantaris muscle, including types I, IIa, IIb, IIa/b and IIx. Different fiber types are known to have distinct CSAs and a shift of relative fiber type frequency among different experimental and control groups could potentially confound the quantitative analysis for CSA and fiber numbers ([Figure 3D, E, F](#fig3){ref-type="fig"}) especially when only a subset of the section is analyzed. Particularly, [Figure 3D](#fig3){ref-type="fig"} did not show appreciable difference between the fiber CSA of *myomaker*^scKO^ MOV and Sham controls but a clear shift towards larger myofiber sizes of *myomaker*^scKO^ MOV is observed in 3E. An analysis of relative fiber type frequency and the CSA of each fiber type is necessary for clarifying and validating the quantitative claims and achievable by re-staining the current section slides.

6\) [Figure 2C](#fig2){ref-type="fig"} shows an increase at day 7 and then dramatic decrease of lacz^+^ mononuclear cells by day 10 after MOV. The authors effectively show that the accumulated lacz^+^ cells do not fuse into fibers, but they have not explained the nearly 10-fold reduction that occurs in just 3 days. Is there evidence of lacz^+^ (or lacz^-^) muscle progenitor cell apoptosis during this interval, or are the cells simply shutting down expression of myomaker? Clarification of this point is important for interpreting the results, and could be obtained by ([@bib1]) an analysis of lacz^+^ MP apoptosis rates at multiple time points after MOV (days 3, 7, 10 and 14) and ([@bib2]) analysis of MP cell number and apoptosis rates at additional time points after MOV using the mTmG model, in which cells are permanently marked with GFP, so should be trackable regardless of whether they downregulate myomaker. Relatedly, an inherent assumption in the authors\' discussion of contrasting results in the DTA ablation model versus myomaker deletion model is that myomaker deletion does not affect the frequency of muscle stem cells (satellite cells) in MOV muscles; however, this is not demonstrated directly. The authors should quantify satellite cell numbers in scKO versus control MOV muscles to directly evaluate effects of myomaker loss in the MOV model on maintenance of muscle regenerative cells.

7\) The authors appear to use the same results in different ways, generating more figure panels (e.g. [Figure 1C-G](#fig1){ref-type="fig"}, [2B-D](#fig2){ref-type="fig"}, [3C-E](#fig3){ref-type="fig"}, [4B, C, F, G](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}). While this approach is used occasionally in the literature to help the reader\'s understanding, in this paper, it\'s overused. Data presentation should be revised so that one source of results is used for one figure panel.

8\) In [Figure 3F](#fig3){ref-type="fig"}, fusion of MP to myofiber significantly increased fiber number whereas myomaker KO in SC decreased the levels to that of the control. If two cells fuse, shouldn\'t the produce be one cell in a larger volume, as shown by a dramatic increase in muscle mass ([Figure 3B](#fig3){ref-type="fig"})? Does this mean that myomaker is required for the increase in fiber number? The authors do not explain this important observation, and rather described it as an inability of MP to fuse. They should explain this finding about the role of myomaker in this process more clearly. This result shows that myomaker is required not only for the hypertrophy but also for the increase in fiber number.

9\) Because the results in [Figure 4C](#fig4){ref-type="fig"} show that 30% of myofibers are engaged in fusion, the \~2.5 fold increase in muscle size in [Figure 3B](#fig3){ref-type="fig"} seems to be a quite surprising. The increase in Fiber CSA seems to be consistent with [Figure 4C](#fig4){ref-type="fig"}. Does this mean myofibers become much denser? The authors should address this gap between the marked increase (2.5-fold) in muscle mass and the relatively small fraction (30%) of myotubes involved infusion.

10\) [Figure 5](#fig5){ref-type="fig"} seems to be very superficial, although the control of hypertrophy by myomaker is the main point of this manuscript. This pathway, AKT/mTOR, exists not only in the progenitor but also in myofibers. Thus, it is not new that the signaling pathway (i.e. p-AKT, p-S6K) is decreased by compromised hypertrophy. This should be discussed in the manuscript, along with the need to uncover the mechanistic basis for this result.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Requirement of myomaker-mediated stem cell fusion for skeletal muscle hypertrophy\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Sean Morrison (Senior Editor), and Amy Wagers (Reviewing Editor).

We appreciate your responsiveness to the prior review, and agree that the manuscript has been substantially improved. However, there are some remaining issues that need to be addressed before acceptance, as outlined below:

1\) The authors' conclusion that satellite cell frequency is not impacted in the scMyomaker mice under MOV ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}) is not convincing because ([@bib1]) the representative FACS plots show a very apparent loss of GFP^+^ cells in the scMyomaker group, even if the quantification indicates that this is not significant for n=3 mice, and a quick power analysis of this experiment, assuming that error bars represent SEM, suggests that the study may be underpowered to detect a difference, and more animals should be analyzed, ([@bib2]) it appears from the Methods that the authors have not included live/dead discrimination in the FACS gating strategy, which will increase \"noise\" in their analyses by including variable amounts of debris and dead cells, and ([@bib3]) as the authors appropriately point out in the Discussion, their analysis of% GFP^+^ cells is influenced not only by possible changes in the satellite cell subset, but also by changes in the numbers of non-myogenic (inflammatory, fibrotic, etc.) cells, which could be influenced indirectly by fusion-deficits caused by myomaker deletion. With all of these caveats, it seems inappropriate to draw a strong conclusion from these data. Furthermore, the Pax7 immunostaining data provided by the authors in support of their conclusion shows only single fields, and is not quantified. The authors should address this concern by either improving the robustness of their FACS analysis or providing quantification of the Pax7 immunostaining assays (or both).

2\) The authors need to specify in every figure legend (including supplemental figures) whether error bars represent SD or SEM.

3\) Regarding the statement in the Results that \"30% of fibers underwent fusion\", the authors should include comment that this is likely an underestimate (and explain why) in the Results section (subsection "Fusion during MOV is blocked through deletion of myomaker in SCs") when these data are first discussed. They do this well in the Discussion, but it should be noted at the time the data are presented as well.

10.7554/eLife.20007.016

Author response

*Essential revisions:*

*1) Ideally, the impact of fusion blockade by ablation of myomaker in muscle progenitor cells would be further supported by evaluation of muscle contractile function. This is important in order to establish the essential contribution of myomaker-mediated stem cell fusion during physiological muscle hypertrophy. Both whole-muscle and single-fiber function assays have been reported previously for MOV systems (Fry et al. 2014 FASEB journal), and inclusion of one of these types of analyses would greatly strengthen the paper. However, the reviewers recognize that these studies may prove difficult to complete in a timely fashion, and so, if the authors are unable to include them in a revised manuscript, they should instead add a comment to the paper\'s discussion indicating that such physiology studies will be important to evaluate in future studies.*

We completely agree that whole-muscle and/or single-fiber assays for muscle contractile function would be valuable in establishing greater physiological relevance for myomaker-mediated stem cell fusion during overload-induced muscle hypertrophy. However, as mentioned by the reviewers we are unable to complete such experiments in a timely manner but have included a comment in our Discussion on the need for assessing contractile function in follow-up studies (fourth paragraph).

*2) In [Figure 1C, D](#fig1){ref-type="fig"}, and E, how do the authors recognize mononuclear cells and fully differentiated myocytes? How do they distinguish the location of blue color in day 3, 7, 10 and 14 in [Figure 1C](#fig1){ref-type="fig"}? Lots of blue color appears inside cells, not on the membrane. Does this mean that myomaker is not a membrane protein in myotubes? These are critical points and should be explained and documented by clear experiments.*

We agree with the reviewers that more detailed investigations are justified to distinguish the various LacZ^+^ cells. We have performed more experiments to address these concerns and also clarified the nature of the *Tmem8c*^LacZ/+^ mouse, which contains a *LacZ* cassette in intron 1 of the myomaker locus. Directly upstream of *LacZ* is a strong splice acceptor site that enables splicing of exon 1 of myomaker and *LacZ*, and an IRES sequence, which allows independent translation of *LacZ*. This allele does not result in a myomaker-LacZ fusion protein, and therefore does not function as a readout for myomaker localization. We only use this allele as a surrogate for myomaker transcription. We have explained these issues in great detail in the Results section (subsection "Dynamic expression of myomaker during muscle overload coincides with fusion", first paragraph).

The reviewers make an excellent point that our initial description of LacZ^+^ cells did not accurately distinguish mononuclear cells and fully differentiated myocytes. Specifically, we observe various types of LacZ^+^ structures after MOV and in this revised manuscript attempted to more clearly articulate the main point of this figure -- that after MOV myomaker expression initially occurs in MPs and then at later stages in myofibers. To deal with this issue we sought to delineate the myogenic state of these LacZ^+^ cells through determining whether these cells were myh3^+^ (embryonic myosin), a known marker for differentiated myocytes. Through staining of day 7 MOV serial sections with either x-gal or myh3 we were able to classify the LacZ^+^ structures. These results are displayed in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} and explained in the Results section (subsection "Dynamic expression of myomaker during muscle overload coincides with fusion", first paragraph). Based on these observations, we have identified the following populations of x-gal^+^ cells:a) Myofibers that exhibit punctate LacZ and are myh3-. We interpret these cells to be existing myofibers that have fused with a LacZ^+^ MP, and the reason for the punctate LacZ is that after fusion LacZ diffuses throughout the large myofiber.

b\) Myofibers that are both LacZ^+^ and myh3^+^, which represent de novo fibers because they express embryonic myosin. These myofibers exhibit stronger LacZ expression, compared to LacZ^+^ myh3^-^ myofibers, because they are formed from the fusion of multiple LacZ^+^ MPs and therefore generate a structure with concentrated LacZ.c) Small LacZ^+^ cells that were either myh3^+^ or myh3^-^. The small LacZ^+^ myh3^+^ cells are differentiated myocytes but they were not large enough to be classified as myofibers as in (b). We interpret the small LacZ^+^ myh3^-^ cells to be MPs given that myomaker is muscle-specific.

For quantitative purposes, we classified the LacZ^+^ cells in (a) and (b) above as 'myofibers', and the small LacZ^+^ cells described in (c) as 'non-myofibers'. We acknowledge there could be many more questions about these data relating to the dynamics of myomaker expression in myogenic lineage progression, however this is not the central point of our manuscript and we think the revised data more effectively substantiates the overall meaning of the figure.

*3) The authors rely extensively on reporter gene expression and mRNA () to track Myomaker protein; however, as commercial antibodies are now available, they should confirm these data by direct staining for myomaker protein in SCs and myofibers.*

We indeed have solely analyzed myomaker expression using qPCR and our LacZ reporter mouse. The reviewers are also correct in that there are commercial antibodies available, and we have also generated two custom antibodies that recognize independent myomaker epitopes. We have tested multiple commercial antibodies as well as our custom antibodies, and these work for western blot and immunostaining on cultured myoblasts. However, the functionality of the antibodies to detect myomaker in vivo on sections is not clear as we observe staining in myomakerscKO samples that we have definitively shown are negative for myomaker mRNA. Moreover, we also observe widespread staining in control sham samples, which is problematic since we have previously demonstrated that unperturbed muscle is myomaker negative through qPCR and LacZ analysis. Therefore, we do not feel comfortable using these reagents to definitively track myomaker protein in SCs and myofibers. While we are attempting to optimize the antibodies for immunostaining, there is no guarantee of success and we think our genetic data in myomakerscKO and myomakermKO mice are sufficient for us to conclude that myomaker is not transcribed from a myonucleus of an existing myofiber during MOV.

*4) Analysis of co-localization of Pax7 and* lacz^+^*in MOV model using the existing subsequent muscle sections is needed to evaluate if satellite cell homing/localization is affected in the hypertrophy model.*

The reviewers raise an important question here. We initially did not perform immunostaining for Pax7 in control or myomakerscKO muscle after MOV. In our revised manuscript, we show that the number and localization of Pax7 cells are not grossly altered in myomakerscKO muscle, compared to control ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}). There could be a small reduction in the number of Pax7 cells in myomakerscKO samples, this is unlikely to be a major factor contributing to the observed hypertrophy defect. Furthermore, our data that loss of myomaker in SCs inhibits fusion during MOV suggests compromised fusion is the central mechanism by which myomakerscKO muscle fails to hypertrophy.

*5) There are multiple muscle fiber types present in the plantaris muscle, including types I, IIa, IIb, IIa/b and IIx. Different fiber types are known to have distinct CSAs and a shift of relative fiber type frequency among different experimental and control groups could potentially confound the quantitative analysis for CSA and fiber numbers ([Figure 3D, E, F](#fig3){ref-type="fig"}) especially when only a subset of the section is analyzed. Particularly, [Figure 3D](#fig3){ref-type="fig"} did not show appreciable difference between the fiber CSA of myomakerscKO MOV and Sham controls but a clear shift towards larger myofiber sizes of myomakerscKO MOV is observed in 3E. An analysis of relative fiber type frequency and the CSA of each fiber type is necessary for clarifying and validating the quantitative claims and achievable by re-staining the current section slides.*

We thank the reviewers for these remarks, which compelled us to more closely analyze our CSA data shown in revised [Figure 3C](#fig3){ref-type="fig"}. The average myofiber CSA in myomakerscKO MOV compared to myomakerscKO sham actually did increase approximately 10% ([Figure 3C](#fig3){ref-type="fig"}), however this was not statistically significant. This is potentially the reason of a shift to larger myofibers, although none of these data points are statistically significant. Overall, these data could suggest that fusion-defective muscle has a minor capacity for hypertrophy and we have now included a paragraph in the Discussion (second paragraph) dealing with this possibility.

Additionally, based on the reviewers suggestions we analyzed the CSA of various fiber types. We stained our muscle sections for type I, type IIa, type IIb, and type IIx muscle fibers, and quantified the CSAs and relative frequency for each fiber type ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Our CSA analysis for the glycolytic fiber types (types IIa, IIb, and IIx) correspond to our main findings of significantly increased myofiber growth in overloaded control muscles, concurrent with impaired myofiber size exhibited by fusion-incompetent muscles across these fiber types. Furthermore, as we observe no more than 2% of the oxidative type 1 fibers in both control and myomaker^scKO^ muscles after overload, we conclude that the majority of myofibers in the plantaris muscle fail to hypertrophy effectively in the absence of satellite cell fusion, regardless of specific fiber types. Despite marked differences in fiber type CSA, relative frequency distribution analyses did not reveal a significant shift towards any particular fiber type after 2 weeks of muscle overload.

*6) [Figure 2C](#fig2){ref-type="fig"} shows an increase at day 7 and then dramatic decrease of* lacz^+^*mononuclear cells by day 10 after MOV. The authors effectively show that the accumulated* lacz^+^*cells do not fuse into fibers, but they have not explained the nearly 10-fold reduction that occurs in just 3 days. Is there evidence of* lacz^+^*(or lacz^-^) muscle progenitor cell apoptosis during this interval, or are the cells simply shutting down expression of myomaker? Clarification of this point is important for interpreting the results, and could be obtained by ([@bib1]) an analysis of* lacz^+^*MP apoptosis rates at multiple time points after MOV (days 3, 7, 10 and 14) and ([@bib2]) analysis of MP cell number and apoptosis rates at additional time points after MOV using the mTmG model, in which cells are permanently marked with GFP, so should be trackable regardless of whether they downregulate myomaker. Relatedly, an inherent assumption in the authors\' discussion of contrasting results in the DTA ablation model versus myomaker deletion model is that myomaker deletion does not affect the frequency of muscle stem cells (satellite cells) in MOV muscles; however, this is not demonstrated directly. The authors should quantify satellite cell numbers in scKO versus control MOV muscles to directly evaluate effects of myomaker loss in the MOV model on maintenance of muscle regenerative cells.*

We thank the reviewers for these valuable comments. We have assessed the presence of muscle progenitors in control and myomakerscKOmuscle after MOV using two independent approaches. First, we used FACs to quantify the percentage of mGFP^+^ MPs, as suggested by the reviewers, and found no significant differences at day 7 or day 10 after MOV between control and myomakerscKOsamples ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}). Second, we performed Pax7 immunostaining and also did not observe a major difference in Pax7^+^ cells during MOV ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}). These data demonstrate that MPs are present in similar quantities, excluding this as a possibility that could underlie the hypertrophy defect.

The reviewers also question the mechanisms by which LacZ^+^ cells are reduced 10 days after MOV, compared to 7 days. We have included a new paragraph in the Discussion (sixth paragraph) dealing with these points.

The reviewers specifically wondered if myomakerscKO LacZ^+^ cells undergo apoptosis between day 7 and 10 of MOV. We assessed this possibility through TUNEL staining as well as a FACs-based cell death approach. We have provided these data for the reviewers (below) but would prefer not to include in the manuscript. The data do not indicate that cell death is the mechanism for the reduction of LacZ^+^ cells, although there is a non-significant increase in% Dead GFP^+^ myomakerscKOMPs. We have also previously shown an increase in TUNEL^+^ cells in developing limbs of myomaker KO mice, which combined with the modest increase in% Dead GFP^+^ cells below could suggest that fusion-defective cells are more prone to cell death. Because there are multiple modes of cell death that should be analyzed through independent strategies, our work examining this process is too preliminary to include, even as a supplemental figure. We think the fate of fusion-defective MPs is an extremely important question that will require more extensive analysis prior to a definitive conclusion. Another reason for our desire to omit the data is that the main point of the manuscript is that SC-mediated fusion is required for overload-induced hypertrophy, not the fate of fusion-defective MPs.10.7554/eLife.20007.014Author response image 1.Analysis of cell death after MOV.(**A**) Representative images of TUNEL^+^nuclei in plantaris sections demonstrates similar rates of apoptosis in control and myomaker^scKO^ muscles following MOV. (**B**) Flow cytometry to distinguish live and dead mGFP^+^ progenitors using a dye that binds to compromised membranes (LIVE/DEAD Fixable Stain, Invitrogen) in tamoxifen-treated *Pax7*^CreERT2/+^; *Rosa*^mTmG^ (control) and *myomaker*^LacZ/loxP^; *Pax7*^CreERT2/+^; *Rosa*^mTmG^ mice (myomaker^scKO^) highlights a small population of dead GFP^+^ cells 7 and 10d after MOV. Quantitative analysis reveals a modest (although non-significant) level of cell death in MPs between control and myomaker^scKO^ muscles at 7 and 10d of MOV (n = 3 mice/group). Scale bar: 10 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.20007.014](10.7554/eLife.20007.014)

*7) The authors appear to use the same results in different ways, generating more figure panels (e.g. [Figure 1C-G](#fig1){ref-type="fig"}, [2B-D](#fig2){ref-type="fig"}, [3C-E](#fig3){ref-type="fig"}, [4B, C, F, G](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}). While this approach is used occasionally in the literature to help the reader\'s understanding, in this paper, it\'s overused. Data presentation should be revised so that one source of results is used for one figure panel.*

We note the overuse of figure panels in our manuscript, and have revised our data presentation to reflect one source of results for each figure panel. In addition, corresponding figure legends have been revised accordingly to reflect these changes.

*8) In [Figure 3F](#fig3){ref-type="fig"}, fusion of MP to myofiber significantly increased fiber number whereas myomaker KO in SC decreased the levels to that of the control. If two cells fuse, shouldn\'t the produce be one cell in a larger volume, as shown by a dramatic increase in muscle mass ([Figure 3B](#fig3){ref-type="fig"})? Does this mean that myomaker is required for the increase in fiber number? The authors do not explain this important observation, and rather described it as an inability of MP to fuse. They should explain this finding about the role of myomaker in this process more clearly. This result shows that myomaker is required not only for the hypertrophy but also for the increase in fiber number.*

The reviewers are accurate and we have similarly interpreted our data, that myomaker is required for an increase in fiber number. We have highlighted this point in our manuscript (subsection "Satellite cell-derived myomaker is required for overload-induced muscle hypertrophy", last paragraph and Discussion, first paragraph). Our current stance on physiological muscle growth in mice is that the hypertrophic response to overload comprises both myofiber growth and the formation of de novo myofibers (hyperplasia), as demonstrated in [Figure 3C](#fig3){ref-type="fig"} and [Figure 3D](#fig3){ref-type="fig"}, respectively. Both these processes are governed by fusion; myofiber growth through fusion of satellite cells to an existing fiber, and hyperplasia through fusion of satellite cells to each other to generate de novo fibers. The increase in fiber number after MOV has been proposed to result from de novo myofiber formation or splitting of existing myofibers. However, to our knowledge, the evidence for myofiber splitting is weak suggesting that increased fiber number is attributed to de novo myofiber formation.

*9) Because the results in [Figure 4C](#fig4){ref-type="fig"} show that 30% of myofibers are engaged in fusion, the \~2.5 fold increase in muscle size in [Figure 3B](#fig3){ref-type="fig"} seems to be a quite surprising. The increase in Fiber CSA seems to be consistent with [Figure 4C](#fig4){ref-type="fig"}. Does this mean myofibers become much denser? The authors should address this gap between the marked increase (2.5-fold) in muscle mass and the relatively small fraction (30%) of myotubes involved infusion.*

In the original manuscript, [Figure 4C](#fig4){ref-type="fig"} ([Figure 4B](#fig4){ref-type="fig"} in the revised version) shows that 30% of myofibers have undergone fusion, which was assessed through BrdU labeling. Given that this is one level of a particular muscle, if a BrdU myonucleus was above or below this plane then that fiber would not be counted as a positive fusion event. Therefore, this BrdU analysis underestimates the extent of fusion that occurs during MOV. Indeed, our lineage tracing analysis ([Figure 4D](#fig4){ref-type="fig"}) shows that the majority of fibers fuse with MPs in response to MOV. We mention these details in the Discussion (first paragraph).

The reviewers bring up an excellent point regarding the discrepancy between muscle weights ([Figure 3B](#fig3){ref-type="fig"}) and myofiber CSA ([Figure 3C](#fig3){ref-type="fig"}). The main reason for this apparent inconsistency is that muscle weights are not the ideal readout for hypertrophy. We originally reported our muscle weights and CSA results as indicators of hypertrophy but have more clearly defined these analyses in the revised manuscript (Results, subsection "Satellite cell-derived myomaker is required for overload-induced muscle hypertrophy", first paragraph). Muscle weights directly measure all components of the tissue, including myofibers, ECM, and immune cell infiltration and do not directly evaluate myofiber size. Moreover, since we remove two-thirds of the gastrocnemius during MOV, it is difficult to reliably dissect the plantaris away from the remaining gastrocnemius. This phenomenon could lead to the disparity between muscle weights and CSA, and reinforces that muscle weights should not be used as a proxy for hypertrophy. In contrast, the most direct assessment of hypertrophy is CSA, which we have emphasized in the revised manuscript.

*10) [Figure 5](#fig5){ref-type="fig"} seems to be very superficial, although the control of hypertrophy by myomaker is the main point of this manuscript. This pathway, AKT/mTOR, exists not only in the progenitor but also in myofibers. Thus, it is not new that the signaling pathway (i.e. p-AKT, p-S6K) is decreased by compromised hypertrophy. This should be discussed in the manuscript, along with the need to uncover the mechanistic basis for this result.*

We agree that findings of associated reductions in Akt/mTOR signaling in fusion-incompetent muscles that demonstrate impaired hypertrophy following mechanical overload would be strengthened by more experiments. Hence, we have included additional experiments to further establish that myomaker-mediated stem cell fusion may augment physiological muscle growth. Specifically, we utilized the antibiotic puromycin to assess muscle protein synthesis, a downstream effector of Akt/mTOR signaling that directly leads to hypertrophy. Here, we report that levels of protein synthesis are elevated in control muscles at both 7 days and 14 days after overload. In contrast, the ability to synthesize proteins is compromised in overloaded myomaker^scKO^ fusion-incompetent muscles ([Figure 5B](#fig5){ref-type="fig"}). These new data suggests a critical role for myonuclear accretion in generating requisite amounts of proteins to meet the increased physiological demands of mechanical overload. Per the reviewers' request, we have also included a line in our manuscript on the need to further uncover the mechanisms by which satellite cell fusion drives muscle hypertrophy (Discussion, third paragraph).

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

*We appreciate your responsiveness to the prior review, and agree that the manuscript has been substantially improved. However, there are some remaining issues that need to be addressed before acceptance, as outlined below:*

*1) The author\'s conclusion that satellite cell frequency is not impacted in the scMyomaker mice under MOV ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}) is not convincing because ([@bib1]) the representative FACS plots show a very apparent loss of* GFP^+^*cells in the scMyomaker group, even if the quantification indicates that this is not significant for n=3 mice, and a quick power analysis of this experiment, assuming that error bars represent SEM, suggests that the study may be underpowered to detect a difference, and more animals should be analyzed, ([@bib2]) it appears from the Methods that the authors have not included live/dead discrimination in the FACS gating strategy, which will increase \"noise\" in their analyses by including variable amounts of debris and dead cells, and ([@bib3]) as the authors appropriately point out in the Discussion, their analysis of%* GFP^+^*cells is influenced not only by possible changes in the satellite cell subset, but also by changes in the numbers of non-myogenic (inflammatory, fibrotic, etc.) cells, which could be influenced indirectly by fusion-deficits caused by myomaker deletion. With all of these caveats, it seems inappropriate to draw a strong conclusion from these data. Furthermore, the Pax7 immunostaining data provided by the authors in support of their conclusion shows only single fields, and is not quantified. The authors should address this concern by either improving the robustness of their FACS analysis or providing quantification of the Pax7 immunostaining assays (or both).*

We agree with the reviewers that there are caveats associated with our FACS analysis, which is why we originally used a secondary method (Pax7 immunostaining) to confirm these data. In this revised version, we have improved our Pax7 immunostaining through use of a biotin-strepavidin detection system (Methods) and quantified the number of Pax7^+^ cells ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}). Specifically, we express the number of Pax7^+^ cells per section or normalize to fiber number. That we do not see a significant difference in SC number when normalized to fiber number suggests that the muscle stem cells are not dramatically reduced in myomaker scKO muscle. We agree with the reviewers that it may be inappropriate to draw stronger conclusions from this data, other than there may be subtle alterations in SC dynamics but the myomaker scKO model does not significantly alter SC frequency. We have scaled back our interpretations of these data within the Results section (subsection "Myomaker is activated primarily in muscle progenitors", first paragraph).

*2) The authors need to specify in every figure legend (including supplemental figures) whether error bars represent SD or SEM.*

We have now specified whether error bars represent SD or SEM within each figure.

*3) Regarding the statement in the Results that \"30% of fibers underwent fusion\", the authors should include comment that this is likely an underestimate (and explain why) in the Results section (subsection "Fusion during MOV is blocked through deletion of myomaker in SCs") when these data are first discussed. They do this well in the Discussion, but it should be noted at the time the data are presented as well.*

We included this statement in the revised version (subsection "Fusion during MOV is blocked through deletion of myomaker in SCs", first paragraph).
